Arkadios Wealth Advisors Has $10.09 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Key Points

• Arkadios Wealth Advisors increased its stake in Johnson & Johnson by 31.7%, acquiring 14,636 shares, bringing its total holdings to 60,828 shares valued at approximately $10.1 million.
• Johnson & Johnson reported better-than-expected quarterly earnings with an EPS of $2.77, exceeding analyst estimates by $0.09, and a revenue of $23.74 billion, up 5.8% from the previous year.
• The company declared a quarterly dividend of $1.30 per share, which translates to an annualized yield of 3.09% and a payout ratio of 55.61%.

Arkadios Wealth Advisors raised its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 31.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 60,828 shares of the company's stock after acquiring an additional 14,636 shares during the quarter. Arkadios Wealth Advisors' holdings in Johnson & Johnson were worth $10,088,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the business. Brighton Jones LLC raised its position in shares of Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock valued at $7,502,000 after purchasing an additional 6,332 shares during the period. Hudson Value Partners LLC increased its position in Johnson & Johnson by 2.5% during the fourth quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock worth $5,648,000 after acquiring an additional 1,022 shares during the period. New Age Alpha Advisors LLC bought a new position in Johnson & Johnson during the fourth quarter worth $665,000. Roundview Capital LLC increased its position in Johnson & Johnson by 19.9% during the fourth quarter. Roundview Capital LLC now owns 70,685 shares of the company's stock worth $10,223,000 after acquiring an additional 11,737 shares during the period. Finally, StoneX Group Inc. increased its position in Johnson & Johnson by 40.5% during the fourth quarter. StoneX Group Inc. now owns 42,849 shares of the company's stock worth $6,197,000 after acquiring an additional 12,359 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Piper Sandler restated an "overweight" rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Wall Street Zen downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research note on Friday, July 18th. Guggenheim restated a "neutral" rating and issued a $167.00 target price (up previously from $164.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. Leerink Partners downgraded shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and reduced their target price for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Finally, The Goldman Sachs Group upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and upped their price target for the stock from $157.00 to $172.00 in a research report on Wednesday, April 9th. Nine investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $174.50.

Johnson & Johnson Stock Performance

JNJ stock traded up $2.59 during trading hours on Friday, hitting $167.33. 8,914,735 shares of the stock were exchanged, compared to its average volume of 9,077,193. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $402.99 billion, a P/E ratio of 17.90, a P/E/G ratio of 2.13 and a beta of 0.41. The company has a 50-day simple moving average of $157.18 and a two-hundred day simple moving average of $156.44. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.09. The firm had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. The company's quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter last year, the business earned $2.82 EPS. On average, analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be given a $1.30 dividend. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.1%. Johnson & Johnson's dividend payout ratio (DPR) is presently 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.